Rubin Amir Dan 4
4 · 1Life Healthcare Inc · Filed Oct 12, 2022
Insider Transaction Report
Form 4
Rubin Amir Dan
DirectorChair, CEO and President
Transactions
- Exercise/Conversion
Common Stock
2022-10-07$4.01/sh+1,128,882$4,526,817→ 1,228,630 total - Exercise/Conversion
Common Stock
2022-10-07$11.56/sh+242,235$2,800,237→ 1,470,865 total - Sale
Common Stock
2022-10-07$17.03/sh−1,371,117$23,348,066→ 99,748 total - Exercise/Conversion
Stock Options (Right to buy)
2022-10-07−1,128,882→ 0 totalExercise: $4.01Exp: 2027-09-13→ Common Stock (1,128,882 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-10-07−242,235→ 2,064,765 totalExercise: $11.56Exp: 2029-11-20→ Common Stock (242,235 underlying)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and were conducted by the reporting person for tax and estate planning purposes. The reporting person has adopted Rule 10b5-1 plans in the past and has adopted this Rule 10b5-1 plan in the ordinary course. The trading plans and their parameters do not reflect the reporting person's views on the closing of the pending, previously announced, merger or the prospects of the Company's business after the closing.
- [F2]This transaction was executed in multiple trades at prices ranging from $16.95 to $17.085. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The shares subject to the option vested as follows: 20% of the shares subject to the option vested on the first anniversary of the vesting commencement date; and 1/60th of the shares subject to the option vested monthly thereafter over the following four years, subject to the reporting person's continuous service as of each such date.
- [F4]The shares subject to the option vest as follows: 63% of the shares subject to the option vest ratably on a monthly basis from the vesting commencement date through August 2023; 25% of the shares subject to the option vest ratably on a monthly basis from September 2023 to August 2024; and the remaining 12% of the shares subject to the option vest ratably on a monthly basis from September 2024 to August 2025, subject to the reporting person's continuous service as of each such date.